Iranian Journal of Neurology 2017. 16(1):1-6.

Comparison of the effects of low dose interferon and high dose interferon on reduction of the number and size of plaques in patients with Multiple Sclerosis: A historical cohort
Payam Khomand, Ghobad Moradi, Behrooz Ahsan, Setareh Abtahi


Background: This study was performed to compare the effects of low dose interferon beta-1 (IFN-β-1) (CinnoVex, 30 mcg) and high dose
IFN-β-1 (REBIF, 44 mcg) on the reduction of the number and size of plaques in magnetic resonance imaging (MRI) in patients with multiple sclerosis (MS).

Methods: This historical cohort study, which was performed in 2014 in Sanandaj (western part of Iran). 43 MS patients in two groups were investigated. The first group, which included 19 patients, was treated using high dose IFN (44 mcg) and the second group, which was consisted of 24 patients, was treated using low dose IFN (30 mcg). Patients’ data were collected and analyzed by the Stata version 11 software; the analyses were performed using statistical t-test, chi-square test, Fisher test, and logistic regression.

Results: Both drugs were effective in controlling active demyelinating plaque and in preventing plaque activation (P = 0.633). The impact of both drugs in the reduction of the number and size of plaques was evaluated. Based on the results of the MRI, high dose IFN therapy was more effective than the low dose IFN drugs and had a better performance in terms of reducing the number of plaques and in stop-and-recovery (P = 0.039), as well as in reducing the plaque size (P = 0.050).

Conclusion: The high dose IFN therapy was more effective than the low dose IFN therapy in reducing the number and size of brain plaques in patients with relapsing-remitting MS (RRMS).


Multiple Sclerosis; High Dose Interferon; Low Dose Interferon; Magnetic Resonance Imaging

Full Text:



Niedziela, N., M. Adamczyk-Sowa, and K. Pierzchala, Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci.2014; 124: 322-30.

Milo, R. and A. Miller, Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014; 13; 518-24.

Tsang, B.K. and R. Macdonell, Multiple sclerosis- diagnosis, management and prognosis. Aust Fam Physician. 2011; 40


Filippi M, Rocca MA, Barkhof F, Brück W,, et al., Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012; 11; 349-60.

Pittock, S.J., J.H. Noseworthy, and M. Rodriguez, MRI findings in benign multiple sclerosis are variable. J Neurol; 2007. 254: 539-41.

Li T, Xiao H, Li S, Du X., et al., Multiple sclerosis: clinical features and MRI findings in Northern China. Eur J Med Res. 2014; 19: 20.

Mahurkar, S., V. Suppiah, and C. O'Doherty, Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev. 2014; 13: 178-86.

Murdoch, D. and K.A. Lyseng-Williamson, Subcutaneous recombinant interferon-beta-1a (REBIF): a review of its use in relapsing-remitting multiple sclerosis. Drugs, 2005; 65: 1295-312.

Sanford, M. and K.A. Lyseng-Williamson, Subcutaneous recombinant interferon-beta-1a (REBIF(R)): a review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2011; 71: 1865-91.

Devonshire, V.A. and E. Verdun di Cantogno, Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart, for the treatment of multiple sclerosis. Ther Deliv. 2: 1455-65.

Vallittu AM1, Halminen M, Peltoniemi J., et al., Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology, 2002. 58: p. 1786-90.

Martina IS1, van Doorn PA, Schmitz PI,., et al., Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry, 1999. 66. 197-201.

Etemadifar M, M.A. and H. A, Comparing Side effects of Low dose interferon with Avonex in Relapsing Remitting Multiple Sclerosis Patients. Journal of Isfahan Medical School . 2009; 27, 93-7.

Bastianello, S., et al., Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon beta-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurol. 11: p. 125.

Bastianello S1, Giugni E, Amato MP., et al., Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity de fi cits in multiple sclerosis. Funct Neurol. 2011; 27; 163-8.

Lowery-Nordberg M1, Eaton E, Gonzalez-Toledo E., et al., The effects of high dose interferon-beta1a on plasma microparticles: correlation with MRI parameters. J Neuroinflammation. 2011; 8: doi: 10.1186/1742-2094-8-43.

Hartung, H.P., High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother, 2009. 10; 291-309.

Li, D.K., G.J. Zhao, and D.W. Paty, Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology, 2001. 56; 1505-13.

Oliver, B.J., E. Kohli, and L.H. Kasper, Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci. 2011; 302; 96-105.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.